

Sheet 1 of 5

APPLICANT FACESHEET OF FORM PTO-1449 REV 7-80 AUG 03 2001 OIPE U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO MXI-170	SERIAL NO. 09/820,099
LIST OF PUBLICATIONS CITED BY APPLICANT (Please use several sheets if necessary)		APPLICANT Jan G. W. van de Winkel FILING DATE March 27, 2001	
		GROUP 1614 #4	


U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
LA	A1	4,753,894	06/88	Frankel et al.	435	548	
LA	A2	4,943,533	07/90	Mendelsohn et al.	435	240.27	
LA	A3	4,954,617	09/90	Fanger et al.	530	387	
LA	A4	5,084,396	01/92	Morgan, Jr. et al.	430	543	
LA	A5	5,288,477	02/94	Bacus	424	2	
LA	A6	5,558,864	09/96	Bendig et al.	424	130.1	
LA	A7	5,597,569	01/97	Siegall et al.	424	183.1	
LA	A8	5,635,600	06/97	Fanger et al.	530	387.3	
LA	A9	5,610,057	03/97	Shen et al.	430	334	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
LA	A10	EP 0 255 249	02/88	EPO				
LA	A11	WO 91/00360	01/91	PCT				
LA	A12	WO 91/03493	03/91	PCT				
LA	A13	WO 91/05805	05/91	PCT				
LA	A14	WO 91/05871	05/91	PCT				
LA	A15	WO 92/05793	04/92	PCT				
LA	A16	WO 94/08038	04/94	PCT				
LA	A17	WO 94/10332	05/94	PCT				
LA	A18	WO 95/09917	04/95	PCT				
LA	A19	WO 95/16037	06/95	PCT				
LA	A20	WO 95/24220	09/95	PCT				
LA	A21	WO 98/02463	01/98	PCT				
LA	A22	WO 98/23646	06/98	PCT				

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

LA	A23	Alkan, S. et al., "Enhanced Antiproliferative Action of Interferon Targeted by Bispecific Monoclonal Antibodies," <i>Journal of Interferon Research</i> , 8:25-33 (1988)
LA	A24	Bacus, S. et al., "Expression of the erbB-2 Family of Growth Factor Receptors and their Ligands in Breast Cancers," <i>Am J Clin Pathol</i> , 102(S1):S13-S24 (1994)
LA	A25	Bajorath, J. et al., "Comparison of an Antibody Model with an X-Ray Structure: The Variable Fragment of BR96," <i>Proteins: Structure, Function, and Genetics</i> , 24:152-157 (1996)
LA	A26	Chen, J. et al. "An Immunoconjugate of Lys ³ -Bombesin and Monoclonal Antibody 22 Can Specifically Induce FcγRI (CD64)-dependent Monocyte- and Neutrophil-mediated Lysis of Small Cell Carcinoma of the Lung Cells" <i>Clinical Cancer Research</i> 1(4):425-34 (1995)
Examiner		Date Considered
		8/21/02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

David Blahut

1/18/06

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 AUG 03 2001 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO MXI-170	SERIAL NO. 09/820,099
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Jan G. W. van de Winkel	FILING DATE March 27, 2001
	GROUP 1614	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

DB	B1	De Potter, C. and Schelfhout, A., "The Neu-Protein and Breast Cancer," <i>Virchows Archiv</i> , 426:107-115 (1995)
LB	B2	Deo, Y.M. et al., "FcαR directed bispecific molecules (BSM) mediate lysis and phagocytosis of tumor cells," <i>Proc. Ann. Meeting Am. Ass. Can. Res.</i> , 38(1):30, #195 (1997)
LB	B3	Devilee, P. et al., "Recent Developments in the Molecular Genetic Understanding of Breast Cancer," <i>Critical Reviews in Oncogenesis</i> , 5(2 & 3):247-270 (1994)
LB	B4	Earp, H.S. et al., "Heterodimerization and Functional Interaction Between EGF Receptor Family Members: A New Signaling Paradigm with Implications for Breast Cancer Research," <i>Breast Cancer Research and Treatment</i> , 35:115-132 (1995)
LB	B5	Elsässer, D. et al., "Preclinical studies combining bispecific antibodies with cytokine-stimulated effector cells for immunotherapy of renal cell carcinoma," <i>Antican. Res.</i> , 19(2c):1525-1528 (1999)
LB	B6	Fanger, M.W. et al. "Bispecific Antibodies" <i>Critical Reviews in Immunology</i> 12(3,4):101-24 (1992)
LB	B7	Fanger, M.W. et al. "Production and Use Of Anti-FcR Bispecific Antibodies" <i>Immunomethods</i> 4(1):72-81 (1994)
LB	B8	Fridman, W.H. "Fc receptors and immunoglobulin binding factors" <i>The FASEB J.</i> 5:2684-90 (1991)
LB	B9	Fundamental Immunology, p. 242, William E. Paul, M.D. ed., 3 rd edition, (1993)
LB	B10	Gosselin, E. J., et al., "Enhanced antigen presentation using human Fc-gamma-receptor (monocyte/macrophage)-specific immunogens," <i>J. Immunol.</i> , 149(11):3477-81 (1992)
LB	B11	Graziano, R.F. et al. "Construction and Characterization of a Humanized Anti-γ-Ig Receptor Type I (FcγRI) Monoclonal Antibody" <i>J. Immunology</i> 155 (10):4996-5002 (1995)
LB	B12	Grossetête, B. et al., "Impaired Fcα Receptor Expression is Linked to Increased Immunoglobulin A Levels and Disease Progression in HIV-1-Infected Patients," <i>AIDS</i> , 9:229-234 (1995)
LB	B13	Guyre, P.M. et al., "Increased potency Fc-receptor-targeted antigens," <i>Cancer Immunol. Immunother.</i> , 45(3-4):146-8 (1997)
LB	B14	Harris et al., "Therapeutic Antibodies - The Coming of Age," <i>TIBTECH</i> , 11:42-44 (1993)
LB	B15	Heijnen, I.A.F.M., et al., "Antigen targeting to myeloid-specific human Fc-gamma-RI-CD64 triggers enhanced antibody responses in transgenic mice," <i>J. Clin. Invest.</i> 97(2):331-8 (1996)
Examiner		Date Considered 8/21/02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

Handwritten signature: *Handwritten signature*

Handwritten date: 1/18/06

APPLICANT FACSIMILE OF FORM PTO-1419 REV 7-80 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE JUN 23 2001 U.S. PATENT & TRADEMARK OFFICE		ATTY DOCKET NO MXI-170	SERIAL NO. 09/820,099
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT Jan G. W. van de Winkel	
		FILING DATE March 27, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

LB	C1	Jardines, L. et al., "neu(c-erbB-2/HER2) and the Epidermal Growth Factor Receptor (EGFR) in Breast Cancer," <i>Pathobiology</i> , 61:268-282 (1993)
LB	C2	Jelley-Gibbs, D.M., et al., "Differences in IgG subclass do not effect immune complex-enhanced T cell activation despite differential binding to antigen presenting cells," <i>Hum Immunol</i> 60(6):469-478 (1999)
LB	C3	Johnson, G. et al., "Seqhunt: A Program to Screen Aligned Nucleotide and Amino Acid Sequences," <i>Methods in Molecular Biology</i> , vol. 51, ch. 1, 1-15 (1995)
LB	C4	Jung, G. et al. "Target cell-induced T cell activation with bi- and trispecific antibody fragments" <i>Eur. J. Immunology</i> 21:2431-35 (1991)
LB	C5	Kawamoto, T. et al. "Polymorphonuclear leukocytes-mediated lysis of A431 cells induced by IgG1 mouse anti-epidermal growth factor receptor monoclonal antibodies" <i>In Vitro Cell. Dev. Biol.</i> 28A(11-12):782-86 (1992)
LB	C6	Keler, T. et al., "Bispecific Antibody (MDX-210) Targeting of Tumor Cells to Monocytes Via the Fc Receptor Type I (FcγRI) Promotes Antibody Dependent Cellular Cytotoxicity (ADCC) and Induction of Specific Cytokines," <i>Proc. Am. Assoc. Can. Res.</i> , 36:485, Abstr. 2892 (1995)
LB	C7	Kettleborough, C. A. et al. "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation" <i>Protein Eng.</i> 4(7):773-83 (1991)
LB	C8	Kubagawa, H. et al., "Cloning of Genes Encoding Possible Murine Fcα Receptors (FcαR)," <i>FASEB J.</i> , 8(4-5):A749, Abstr. 4341 (1994)
LB	C9	Liu, C., et al., "Fc-gamma-RII on human B cells can mediate enhanced antigen presentation," <i>Cellular Immunology</i> 167(2):188-194 (1996)
LB	C10	Liu, C., et al., "Fc-gamma-RI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopes," <i>J. Clin. Invest.</i> 98(9):2001-7 (1996)
LB	C11	Mabondzo, A. et al. "Antibody-dependent cellular cytotoxicity and neutralization of human immunodeficiency virus type 1 by high affinity cross-linking of gp41 to human macrophage Fc IgG receptor using bispecific antibody" <i>J. of General Virology</i> 75(6):1451-56 (1994)
LB	C12	Mezzanzanica, D. et al., "Human Ovarian Carcinoma Lysis by Cytotoxic T Cells Targeted by Bi-specific Monoclonal Antibodies: Analysis of the Antibody Components," <i>Int. J. Cancer</i> , 41:609-15 (1988)
LB	C13	Monteiro, R. et al., "Definition of Immunoglobulin A Receptors on Eosinophils and their Enhanced Expression in Allergic Individuals," <i>J. Clin. Invest.</i> , 92:1681-1685 (1993)
Examiner		Date Considered 8/21/02
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		


 Daniel Blum

11/18/06

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE AUG 2 2001 PATENT & TRADEMARK OFFICE	ATTY DOCKET NO MXI-170	SERIAL NO. 09/820,099
LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT Jan G. W. van de Winkel	
	FILING DATE March 27, 2001	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

BB	D1	Monteiro, R. et al., "Molecular Heterogeneity of Fc α Receptors Detected by Receptor-Specific Monoclonal Antibodies," <i>The Journal of Immunology</i> , 148(6):1764-1770 (1992)
W	D2	Morton, H.C. et al. "Purification and Characterization of Chimeric Human IgA1 and IgA2 Expressed in COS and Chinese Hamster Ovary Cells" <i>The Journal of Immunology</i> 151(9):4743-4752 (1993)
W	D3	Morton, H.C. et al. "Structure and Function of Human IgA Fc Receptors" <i>Critical Reviews in Immunology</i> 16:423-440 (1996)
W	D4	Patry, C. et al., "Fc α Receptors Mediate Release of Tumour Necrosis Factor- α and Interleukin-6 by Human Monocytes Following Receptor Aggregation," <i>Immunology</i> , 86:1-5 (1995)
W	D5	Patry, C. et al., "Identification of Fc α Receptor (CD89) Isoforms Generated by Alternative Splicing that are Differentially Expressed Between Blood Monocytes and Alveolar Macrophages," <i>J Immunol</i> , 156:4442-4448 (1996)
W	D6	Pfefferkorn, L. and Yeaman, G.R., "Association of IgA-Fc Receptors (Fc α R) with Fc ϵ R1 γ 2 Subunits in U937 Cells," <i>The Journal of immunology</i> , 153:3228-3236 (1994)
W	D7	Posey, J., et al., "Pilot trial of MDX-H210 and GM-CSF for patients with advanced ERB-2 positive malignancies," <i>Proc. Ann. Meeting Am. Ass. Can. Res.</i> , p. 165, Abstr. 1136 (1996)
W	D8	Repp, R. et al. "G-CSF Stimulated Neutrophils As Effector Cells In Immunotherapy With A Bispecific Antibody to Fc γ 1 and To HER-2/neu (MDX210): Preclinical Studies" <i>Immunobiology</i> , 191(2-3):250-51 (1994)
W	D9	Shen, L. et al., "My 43, A Monoclonal Antibody That Reacts with Human Myeloid Cells Inhibits Monocyte IgA Binding and Triggers Function," <i>Journal of Immunol.</i> , 143(12):4117-4122 (1989)
W	D10	Shen, L., "Receptors for IgA on Phagocytic Cells," <i>Immunol. Res.</i> , 11:273-282 (1992)
W	D11	Shen, L. "A monoclonal Antibody Specific for Immunoglobulin A Receptor Triggers Polymorphonuclear Superoxide Release" <i>Journal of Leucocyte Biology</i> 51(4):373-378 (1992)
W	D12	Shimada, T. et al., "Comparative Analysis of Fc α R on Neutrophils and Monocytes," <i>FASEB J.</i> , 9(4):A804, Abstr. 4658 (1995)
W	D13	Shimo, K. et al., "Ligand-Binding Properties of Recombinant Soluble Fc α Receptor," <i>FASEB J.</i> , 9(4):A774, Abstr. 4484 (1995)
W	D14	Threlkeld, S.C. et al., "Differential Down-Modulation of IgA Fc Receptors (Fc α R) on Neutrophils and Monocytes in HIV-Infected and Normal Individuals," <i>FASEB J.</i> , 8(4-5):A492, Abstr. 2851 (1994)

Examiner	Date Considered
<i>[Signature]</i>	8/21/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Paul D. White

1/18/06

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO MXI-170	SERIAL NO. 09/820,099
	APPLICANT Jan G. W. van de Winkel	
	FILING DATE March 27, 2001	GROUP 1614


U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)

BB	E1	Valone, F.H. et al., "Phase Ia/Ib Trial of Bispecific Antibody MDX-210 in Patients with Advanced Breast or Ovarian Cancer that Overexpresses the Proto-Oncogene HER-2/neu," <i>J Clin Oncol</i> , 13(9):2281-2292 (1995)
BB	E2	Valone, F.H. et al., "Schedule Dependent Immunological Stimulation by Bispecific Antibody (BsAb) MDX-210 (anti-FcγRI x anti-HER-2/neu) in Patients with Breast or Ovarian Cancers that Over Express HER-2/neu," <i>Proc. Am. Assoc. Can. Res.</i> , 36:500, Abstr. 2977 (1995)
BB	E3	Webster, D.M. and Rees, A.R., "Molecular Modeling of Antibody-Combining Sites," <i>Methods in Molecular Biology</i> , 51:17-49 (1995)
BB	E4	Weiner, L.M., et al., "Phase I trial of 2B1, a bispecific monoclonal antibody targeting C-ERBB-2 and FcγRIII," <i>Cancer Res.</i> , 55(20):4586-93 (1995)
BB	E5	Weisbart, R.H. et al., "GM-CSF Induces Human Neutrophil IgA-Mediated Phagocytosis by an IgA Fc Receptor Activation Mechanism," <i>Nature</i> , 332:647-648 (1988);
BB	E6	Yeaman, G. et al., "IgA-Fc Receptors (FcαR) on U937 Cells Associate with FcεRI Gamma Subunits," <i>FASEB J.</i> , 8(4-5):A981, Abstr. 5677 (1994)
BB	E7	Briere, F. et al. "Induction of the receptor of the Fc portion of IgA by secretory IgA on human T cell lines and T cell clones" <i>Eur. J. Immunol.</i> 18(3):445-450 (Mar 1988), abstract
BB	E8	Tokumoto, H. et al. "Monoclonal Antibody (G6) Inhibiting IgA Binding to Fixed FcαR(+) T2D4 Cells" <i>Monogr. Allergy</i> 24:208-214 (1988)
Examiner		
Date Considered	8/21/02	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



1/18/06

RECEIVED


 OIP
 JAN 22 2012
 PATENT & TRADEMARK OFFICE

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

10	F1	Deo, Y.M. et al., "Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood," <i>J. Immunol.</i> 1998 Feb 15;160(4):1677-86
24	F2	Van Egmond, M. et al., "FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity," <i>Nat. Med.</i> 2000 Jun;6(6):680-5
100	F3	Huls, G. et al., "Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies," <i>Cancer Res.</i> 1999 Nov 15;59(22):5778-84
100	F4	Pai, L.H. et al., "Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of <i>Pseudomonas</i> exotoxin," <i>PNAS USA</i> 1991 Apr 15;88(8):3358-62
100	F5	Valerius, T. et al., "FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy," <i>Blood</i> 1997 Dec 1;90(11):4485-92
Examiner		8/21/02
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>		

Paul Blund

11/18/06